10-Q 1 lxrx930201410-q.htm 10-Q
Table of Contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)

R | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period Ended September 30, 2014
or

q | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Transition Period from _____________ to _____________
Commission File Number: 000-30111
Lexicon Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in its Charter)

Delaware | 76-0474169
(State or Other Jurisdiction of Incorporation or Organization) | (I.R.S. Employer Identification Number)

8800 Technology Forest Place
The Woodlands, Texas 77381
(Address of Principal Executive Offices and Zip Code)
(281) 863-3000
(Registrant’s Telephone Number, Including Area Code)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.

Yes | þ |  | No |

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes | þ |  | No |

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer Accelerated filer þ Non-accelerated filer Smaller reporting company
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes |  |  | No | þ

As of November 4, 2014, 514,834,527 shares of the registrant’s common stock, par value $0.001 per share, were outstanding.

Table of Contents
Lexicon Pharmaceuticals, Inc.
Table of Contents

|  | Page
Factors Affecting Forward-Looking Statements | 2
Part I – Financial Information | 3
Item 1. | Financial Statements | 3
| Consolidated Balance Sheets – September 30, 2014 (unaudited) and December 31, 2013 | 3
| Consolidated Statements of Comprehensive Loss (unaudited) – Three and Nine Months Ended September 30, 2014 and 2013 | 4
| Consolidated Statements of Stockholders’ Equity (unaudited) – Nine Months Ended September 30, 2014 and 2013 | 5
| Consolidated Statements of Cash Flows (unaudited) – Nine Months Ended September 30, 2014 and 2013 | 6
| Notes to Consolidated Financial Statements (unaudited) | 7
Item 2. | Management’s Discussion and Analysis of Financial Condition and Results of Operations | 14
Item 3. | Quantitative and Qualitative Disclosures About Market Risk | 19
Item 4. | Controls and Procedures | 19
Part II – Other Information | 20
Item 1. | Legal Proceedings | 20
Item 1A. | Risk Factors | 20
Item 6. | Exhibits | 22
Signatures |  | 23

The Lexicon name and logo are registered trademarks of Lexicon Pharmaceuticals, Inc.
——————
Factors Affecting Forward Looking Statements
This quarterly report on Form 10-Q contains forward-looking statements. These statements relate to future events or our future financial performance. We have attempted to identify forward-looking statements by terminology including “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “should” or “will” or the negative of these terms or other comparable terminology. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including the risks outlined under “Part II, Item 1A. - Risk Factors,” that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels or activity, performance or achievements expressed or implied by these forward-looking statements.
Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. We are not under any duty to update any of the forward-looking statements after the date of this quarterly report on Form 10-Q to conform these statements to actual results, unless required by law.
2

Table of Contents
Part I – Financial Information
Item 1. Financial Statements
Lexicon Pharmaceuticals, Inc.
Consolidated Balance Sheets
(In thousands, except par value)

|  | As of September 30, |  | As of December 31,
|  | 2014 |  | 2013
Assets |  | (unaudited) |  |
Current assets: |  |  |  |
Cash and cash equivalents |  | $ | 26,775 |  |  | $ | 37,499 |
Short-term investments, including restricted investments of $430 |  | 31,094 |  |  | 91,629 |
Accounts receivable, net of allowances of $35 |  | 165 |  |  | 790 |
Assets held for sale |  | 23,849 |  |  | — |
Prepaid expenses and other current assets |  | 5,937 |  |  | 4,636 |
Total current assets |  | 87,820 |  |  | 134,554 |
Property and equipment, net of accumulated depreciation and amortization of $48,743 and $81,945, respectively |  | 1,494 |  |  | 41,362 |
Goodwill |  | 44,543 |  |  | 44,543 |
Other intangible assets |  | 53,557 |  |  | 53,557 |
Other assets |  | 108 |  |  | 144 |
Total assets |  | $ | 187,522 |  |  | $ | 274,160 |
Liabilities and Equity |  |  |  |
Current liabilities: |  |  |  |
Accounts payable |  | $ | 9,741 |  |  | $ | 9,715 |
Accrued liabilities |  | 13,134 |  |  | 7,674 |
Current portion of deferred revenue |  | 785 |  |  | 195 |
Current portion of long-term debt |  | 20,609 |  |  | 1,710 |
Total current liabilities |  | 44,269 |  |  | 19,294 |
Deferred revenue, net of current portion |  | 12,679 |  |  | 13,405 |
Long-term debt |  | — |  |  | 20,167 |
Deferred tax liabilities |  | 18,745 |  |  | 18,745 |
Other long-term liabilities |  | 34,005 |  |  | 32,386 |
Total liabilities |  | 109,698 |  |  | 103,997 |
Commitments and contingencies |  |  |  |
Equity: |  |  |  |
Preferred stock, $.01 par value; 5,000 shares authorized; no shares issued and outstanding |  | — |  |  | — |
Common stock, $.001 par value; 900,000 shares authorized; 516,116 and 514,349 shares issued, respectively |  | 516 |  |  | 514 |
Additional paid-in capital |  | 1,181,015 |  |  | 1,175,108 |
Accumulated deficit |  | (1,101,319 | ) |  | (1,003,958 | )
Accumulated other comprehensive gain |  | 2 |  |  | 2 |
Treasury stock, at cost, 1,281 and 814 shares, respectively |  | (2,390 | ) |  | (1,503 | )
Total equity |  | 77,824 |  |  | 170,163 |
Total liabilities and equity |  | $ | 187,522 |  |  | $ | 274,160 |

The accompanying notes are an integral part of these consolidated financial statements.
3

Table of Contents
Lexicon Pharmaceuticals, Inc.
Consolidated Statements of Comprehensive Loss
(In thousands, except per share amounts)
(Unaudited)

|  | Three Months Ended September 30, |  | Nine Months Ended September 30,
|  | 2014 |  | 2013 |  | 2014 |  | 2013
Revenues: |  |  |  |  |  |  |  |
Collaborative research |  | $ | 312 |  |  | $ | 238 |  |  | $ | 1,111 |  |  | $ | 733 |
Subscription and license fees |  | 107 |  |  | — |  |  | 261 |  |  | 79 |
Total revenues |  | 419 |  |  | 238 |  |  | 1,372 |  |  | 812 |
Operating expenses: |  |  |  |  |  |  |  |
Research and development, including stock-based compensation of $797, $1,027, $3,195 and $3,379, respectively |  | 24,108 |  |  | 25,400 |  |  | 69,248 |  |  | 69,419 |
Increase (decrease) in fair value of Symphony Icon, Inc. purchase liability |  | (1,072 | ) |  | 1,338 |  |  | 518 |  |  | 3,079 |
General and administrative, including stock-based compensation of $697, $723, $2,389 and $2,349, respectively |  | 4,617 |  |  | 4,716 |  |  | 15,423 |  |  | 13,709 |
Impairment loss on buildings |  | 13,102 |  |  | — |  |  | 13,102 |  |  | — |
Total operating expenses |  | 40,755 |  |  | 31,454 |  |  | 98,291 |  |  | 86,207 |
Loss from operations |  | (40,336 | ) |  | (31,216 | ) |  | (96,919 | ) |  | (85,395 | )
Interest income |  | 5 |  |  | 39 |  |  | 17 |  |  | 136 |
Interest expense |  | (449 | ) |  | (492 | ) |  | (1,361 | ) |  | (1,494 | )
Other income, net |  | 282 |  |  | 11 |  |  | 902 |  |  | 41 |
Consolidated net loss |  | $ | (40,498 | ) |  | $ | (31,658 | ) |  | $ | (97,361 | ) |  | $ | (86,712 | )
Consolidated net loss per common share, basic and diluted |  | $ | (0.08 | ) |  | $ | (0.06 | ) |  | $ | (0.19 | ) |  | $ | (0.17 | )
Shares used in computing consolidated net loss per common share, basic and diluted |  | 514,796 |  |  | 513,419 |  |  | 514,461 |  |  | 512,980 |
Other comprehensive loss: |  |  |  |  |  |  |  |
Unrealized gain (loss) on investments |  | (3 | ) |  | 7 |  |  | — |  |  | 15 |
Comprehensive loss |  | $ | (40,501 | ) |  | $ | (31,651 | ) |  | $ | (97,361 | ) |  | $ | (86,697 | )

The accompanying notes are an integral part of these consolidated financial statements.
4

Table of Contents
Lexicon Pharmaceuticals, Inc.
Consolidated Statements of Stockholders’ Equity
(In thousands)
(Unaudited)

|  | Common Stock |  | Additional |  |  |  | Accumulated Other |  |  |  |
|  | Shares |  | Par Value |  | Paid-In Capital |  | Accumulated Deficit |  | Comprehensive Gain |  | Treasury Stock |  | Total
Balance at December 31, 2012 |  | 512,375 |  |  | $ | 512 |  |  | $ | 1,166,605 |  |  | $ | (899,832 | ) |  | $ | 23 |  |  | $ | (630 | ) |  | $ | 266,678 |
Stock-based compensation |  | — |  |  | — |  |  | 5,728 |  |  | — |  |  | — |  |  | — |  |  | 5,728 |
Issuance of common stock under Equity Incentive Plans |  | 1,900 |  |  | 2 |  |  | 872 |  |  | — |  |  | — |  |  | — |  |  | 874 |
Repurchase of common stock |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (873 | ) |  | (873 | )
Net loss |  | — |  |  | — |  |  | — |  |  | (86,712 | ) |  | — |  |  | — |  |  | (86,712 | )
Unrealized gain on investments |  | — |  |  | — |  |  | — |  |  | — |  |  | 15 |  |  | — |  |  | 15 |
Balance at September 30, 3013 |  | 514,275 |  |  | $ | 514 |  |  | $ | 1,173,205 |  |  | $ | (986,544 | ) |  | $ | 38 |  |  | $ | (1,503 | ) |  | $ | 185,710 |
Balance at December 31, 2013 |  | 514,349 |  |  | $ | 514 |  |  | $ | 1,175,108 |  |  | $ | (1,003,958 | ) |  | $ | 2 |  |  | $ | (1,503 | ) |  | $ | 170,163 |
Stock-based compensation |  | — |  |  | — |  |  | 5,584 |  |  | — |  |  | — |  |  | — |  |  | 5,584 |
Issuance of common stock under Equity Incentive Plans |  | 1,767 |  |  | 2 |  |  | 323 |  |  | — |  |  | — |  |  | — |  |  | 325 |
Repurchase of common stock |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (887 | ) |  | (887 | )
Net loss |  | — |  |  | — |  |  | — |  |  | (97,361 | ) |  | — |  |  | — |  |  | (97,361 | )
Balance at September 30, 2014 |  | 516,116 |  |  | $ | 516 |  |  | $ | 1,181,015 |  |  | $ | (1,101,319 | ) |  | $ | 2 |  |  | $ | (2,390 | ) |  | $ | 77,824 |

The accompanying notes are an integral part of these consolidated financial statements.
5

Table of Contents
Lexicon Pharmaceuticals, Inc.
Consolidated Statements of Cash Flows
(In thousands)
(Unaudited)

|  | Nine Months Ended September 30,
|  | 2014 |  | 2013
Cash flows from operating activities: |  |  |  |
Consolidated net loss |  | $ | (97,361 | ) |  | $ | (86,712 | )
Adjustments to reconcile consolidated net loss to net cash used in operating activities: |  |  |  |
Depreciation |  | 1,724 |  |  | 2,194 |
Impairment of fixed assets |  | 13,344 |  |  | — |
Increase in fair value of Symphony Icon, Inc. purchase liability |  | 518 |  |  | 3,079 |
Stock-based compensation |  | 5,584 |  |  | 5,728 |
Gain on disposal of property and equipment |  | (811 | ) |  | — |
Changes in operating assets and liabilities: |  |  |  |
Decrease in accounts receivable |  | 625 |  |  | 483 |
Increase in prepaid expenses and other current assets |  | (1,301 | ) |  | (908 | )
Decrease in other assets |  | 63 |  |  | 62 |
Increase in accounts payable and other liabilities |  | 6,587 |  |  | 6,684 |
Increase (decrease) in deferred revenue |  | (136 | ) |  | 52 |
Net cash used in operating activities |  | (71,164 | ) |  | (69,338 | )
Cash flows from investing activities: |  |  |  |
Purchases of property and equipment |  | (46 | ) |  | (1,506 | )
Proceeds from disposal of property and equipment |  | 1,808 |  |  | 108 |
Purchases of investments |  | (20,651 | ) |  | (80,954 | )
Maturities of investments |  | 81,186 |  |  | 142,125 |
Net cash provided by investing activities |  | 62,297 |  |  | 59,773 |
Cash flows from financing activities: |  |  |  |
Proceeds from issuance of common stock |  | 325 |  |  | 874 |
Repurchase of common stock |  | (887 | ) |  | (873 | )
Repayment of debt borrowings |  | (1,268 | ) |  | (1,167 | )
Other financing activities |  | (27 | ) |  | (111 | )
Net cash used in financing activities |  | (1,857 | ) |  | (1,277 | )
Net decrease in cash and cash equivalents |  | (10,724 | ) |  | (10,842 | )
Cash and cash equivalents at beginning of period |  | 37,499 |  |  | 30,423 |
Cash and cash equivalents at end of period |  | $ | 26,775 |  |  | $ | 19,581 |
Supplemental disclosure of cash flow information: |  |  |  |
Cash paid for interest |  | $ | 1,355 |  |  | $ | 1,437 |
Supplemental disclosure of non-cash investing and financing activities: |  |  |  |
Unrealized gain on investments |  | $ | — |  |  | $ | 15 |

The accompanying notes are an integral part of these consolidated financial statements.
6

Table of Contents
Lexicon Pharmaceuticals, Inc.
Notes to Consolidated Financial Statements
(Unaudited)
1. Basis of Presentation
The accompanying unaudited consolidated financial statements of Lexicon Pharmaceuticals, Inc. (“Lexicon” or the “Company”) have been prepared in accordance with generally accepted accounting principles for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements.
In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the nine-month period ended September 30, 2014 are not necessarily indicative of the results that may be expected for the year ended December 31, 2014.
The accompanying consolidated financial statements include the accounts of Lexicon and its wholly-owned subsidiaries. Intercompany transactions and balances are eliminated in consolidation.
For further information, refer to the financial statements and footnotes thereto included in Lexicon’s annual report on Form 10-K for the year ended December 31, 2013, as filed with the SEC.
2. Net Loss Per Share
Net loss per share is computed using the weighted average number of shares of common stock outstanding during the applicable period and excludes shares underlying stock options and restricted stock units because they are antidilutive. There are no differences between basic and diluted net loss per share for all periods presented.
3. Stock-Based Compensation
The Company recorded $1.5 million and $1.8 million of stock-based compensation expense for the three months ended September 30, 2014 and 2013, respectively, and $5.6 million and $5.7 million of stock-based compensation expense for the nine months ended September 30, 2014 and 2013, respectively. The Company utilized the Black-Scholes valuation model for estimating the fair value of the stock compensation granted, with the following weighted-average assumptions for options granted in the nine months ended September 30, 2014 and 2013:

|  | Expected Volatility |  | Risk-free Interest Rate |  | Expected Term |  | Dividend Rate
September 30, 2014: |  |  |  |  |  |  |  |
Employees |  | 66 | % |  | 1.2 | % |  | 4 |  | — | %
Officers and non-employee directors |  | 80 | % |  | 2.3 | % |  | 8 |  | — | %
September 30, 2013: |  |  |  |  |  |  |  |
Employees |  | 85 | % |  | 0.9 | % |  | 5 |  | — | %
Officers and non-employee directors |  | 81 | % |  | 1.6 | % |  | 8 |  | — | %

7

Table of Contents
The following is a summary of option activity under Lexicon’s stock-based compensation plans for the nine months ended September 30, 2014:

|  | Options |  | Weighted Average Exercise Price
|  | (in thousands) |  |
Outstanding at December 31, 2013 |  | 23,306 |  |  | $ | 2.42 |
Granted |  | 4,287 |  |  | 1.70 |
Exercised |  | (223 | ) |  | 1.46 |
Expired |  | (2,411 | ) |  | 3.97 |
Forfeited |  | (646 | ) |  | 1.97 |
Outstanding at September 30, 2014 |  | 24,313 |  |  | 2.16 |
Exercisable at September 30, 2014 |  | 17,311 |  |  | $ | 2.29 |

During the nine months ended September 30, 2014, Lexicon also granted its employees annual restricted stock units. These restricted stock units vest in four annual installments. The following is a summary of restricted stock units activity under Lexicon’s stock-based compensation plans for the nine months ended September 30, 2014:

|  | Shares |  | Weighted Average Grant Date Fair Value
|  | (in thousands) |  |
Outstanding at December 31, 2013 |  | 4,242 |  |  | $ | 1.93 |
Granted |  | 1,604 |  |  | 1.72 |
Vested |  | (1,384 | ) |  | 1.90 |
Forfeited |  | (1,300 | ) |  | 1.92 |
Nonvested at September 30, 2014 |  | 3,162 |  |  | $ | 1.84 |

During the nine months ended September 30, 2014, Lexicon granted its non-employee directors 102,560 shares of restricted stock awards. The restricted stock awards had a weighted average grant date fair value of $1.56 per share and vested immediately. During the nine months ended September 30, 2014, Lexicon granted a consultant 57,400 shares of restricted stock awards. The restricted stock awards had a weighted average grant date fair value of $1.60 per share and vested immediately.
4. Recent Accounting Pronouncements
In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, “Revenue with Contracts with Customers”, which amends FASB ASC Topic 606. ASU 2014-09 provides a single, comprehensive revenue recognition model for all contracts with customers. This standard contains principles for the determination of the measurement of revenue and the timing of when such revenue is recognized. Revenue recognition will reflect the transfer of goods or services to customers at an amount that is expected to be earned in exchange for those goods or services. This pronouncement is effective for fiscal years, and interim periods within those years, beginning after December 15, 2016, and early adoption is not permitted. Management is currently evaluating the impact of this pronouncement on Lexicon’s consolidated financial statements.
In August 2014, the FASB issued ASU No. 2014-15, “Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern.” ASU 2014-15 will explicitly require management to assess an entity’s ability to continue as a going concern, and to provide related footnote disclosure in certain circumstances. This pronouncement is effective for fiscal years, and interim periods within those years, beginning after December 15, 2016, and early adoption is permitted. Management is currently evaluating the impact of this pronouncement on Lexicon’s consolidated financial statements.
8

Table of Contents
5. Cash and Cash Equivalents and Investments
The fair value of cash and cash equivalents and investments held at September 30, 2014 and December 31, 2013 are as follows:

|  | As of September 30, 2014
|  | Amortized Cost |  | Gross Unrealized Gains |  | Gross Unrealized Losses |  | Estimated Fair Value
|  | (in thousands)
Cash and cash equivalents |  | $ | 26,775 |  |  | $ | — |  |  | $ | — |  |  | $ | 26,775 |
Securities maturing within one year: |  |  |  |  |  |  |  |
Certificates of deposit |  | 552 |  |  | — |  |  | — |  |  | 552 |
U.S. treasury securities |  | 30,540 |  |  | 2 |  |  | — |  |  | 30,542 |
Total short-term investments |  | $ | 31,092 |  |  | $ | 2 |  |  | $ | — |  |  | $ | 31,094 |
Total cash and cash equivalents and investments |  | $ | 57,867 |  |  | $ | 2 |  |  | $ | — |  |  | $ | 57,869 |
|  | As of December 31, 2013
|  | Amortized Cost |  | Gross Unrealized Gains |  | Gross Unrealized Losses |  | Estimated Fair Value
|  |  |  | (in thousands) |  |
Cash and cash equivalents |  | $ | 37,499 |  |  | $ | — |  |  | $ | — |  |  | $ | 37,499 |
Securities maturing within one year: |  |  |  |  |  |  |  |
Certificates of deposit |  | 552 |  |  | — |  |  | — |  |  | 552 |
U.S. treasury securities |  | 91,075 |  |  | 3 |  |  | (1 | ) |  | 91,077 |
Total short-term investments |  | $ | 91,627 |  |  | $ | 3 |  |  | $ | (1 | ) |  | $ | 91,629 |
Total cash and cash equivalents and investments |  | $ | 129,126 |  |  | $ | 3 |  |  | $ | (1 | ) |  | $ | 129,128 |

There were no realized gains or losses for the nine months ended September 30, 2014, and no realized gains or losses for the nine months ended September 30, 2013. The cost of securities sold is based on the specific identification method.
6. Fair Value Measurements
The Company uses various inputs in determining the fair value of its investments and measures these assets on a recurring basis. Assets and liabilities recorded at fair value in the consolidated balance sheets are categorized by the level of objectivity associated with the inputs used to measure their fair value. The following levels are directly related to the amount of subjectivity associated with the inputs to fair valuation of these assets and liabilities:

• | Level 1 - quoted prices in active markets for identical investments, which include U.S. treasury securities

• | Level 2 - other significant observable inputs (including quoted prices for similar investments, market corroborated inputs, etc.)

• | Level 3 - significant unobservable inputs (including the Company’s own assumptions in determining the fair value of the Symphony Icon purchase consideration liability)

9

Table of Contents
The inputs or methodology used for valuing securities are not necessarily an indication of the credit risk associated with investing in those securities. The following table provides the fair value measurements of applicable Company assets and liabilities that are measured at fair value on a recurring basis according to the fair value levels described above as of September 30, 2014 and December 31, 2013.

|  | Assets and Liabilities at Fair Value as of September 30, 2014
|  | Level 1 |  | Level 2 |  | Level 3 |  | Total
|  | (in thousands)
Assets |  |  |  |  |  |  |  |
Cash and cash equivalents |  | $ | 26,775 |  |  | $ | — |  |  | $ | — |  |  | $ | 26,775 |
Short-term investments |  | 30,542 |  |  | 552 |  |  | — |  |  | 31,094 |
Total cash and cash equivalents and investments |  | $ | 57,317 |  |  | $ | 552 |  |  | $ | — |  |  | $ | 57,869 |
Liabilities |  |  |  |  |  |  |  |
Other long-term liabilities |  | $ | — |  |  | $ | — |  |  | $ | 28,228 |  |  | $ | 28,228 |
Total liabilities |  | $ | — |  |  | $ | — |  |  | $ | 28,228 |  |  | $ | 28,228 |

|  | Assets and Liabilities at Fair Value as of December 31, 2013
|  | Level 1 |  | Level 2 |  | Level 3 |  | Total
|  | (in thousands)
Assets |  |  |  |  |  |  |  |
Cash and cash equivalents |  | $ | 37,499 |  |  | $ | — |  |  | $ | — |  |  | $ | 37,499 |
Short-term investments |  | 91,077 |  |  | 552 |  |  | — |  |  | 91,629 |
Total cash and cash equivalents and investments |  | $ | 128,576 |  |  | $ | 552 |  |  | $ | — |  |  | $ | 129,128 |
Liabilities |  |  |  |  |  |  |  |
Other long-term liabilities |  | $ | — |  |  | $ | — |  |  | $ | 27,710 |  |  | $ | 27,710 |
Total liabilities |  | $ | — |  |  | $ | — |  |  | $ | 27,710 |  |  | $ | 27,710 |

The Company’s Level 3 liabilities, which consists of the Symphony Icon purchase consideration liability, is estimated using a probability-based income approach utilizing an appropriate discount rate. Subsequent changes in the fair value of the Symphony Icon purchase consideration liability are recorded as an increase or decrease in Symphony Icon purchase liability expense in the accompanying consolidated statements of comprehensive loss. The following table summarizes the change in consolidated balance sheet carrying value associated with Level 3 liabilities for the nine months ended September 30, 2014 and 2013.

|  | Other Long-term Liabilities
|  | (in thousands)
Balance at December 31, 2013 |  | $ | 27,710 |
Change in valuation of purchase consideration payable to former Symphony Icon stockholders |  | 518 |
Balance at September 30, 2014 |  | $ | 28,228 |
Balance at December 31, 2012 |  | $ | 29,920 |
Change in valuation of purchase consideration payable to former Symphony Icon stockholders |  | 3,079 |
Balance at September 30, 2013 |  | $ | 32,999 |

The Company also has assets that under certain conditions are subject to measurement at fair value on a non-recurring basis. The Company’s buildings and land, which have been classified as assets held for sale (see Note 7, Assets Held for Sale), are measured using Level 2 inputs, based on sale transactions of similar assets, less estimated costs to sell. The Company has executed a letter of intent that supports the estimated selling price, and expects to close the transaction contemplated by this letter of intent within the next year. The Company’s other assets that are subject to measurement at fair value on a non-recurring basis include goodwill associated with the acquisitions of Coelacanth Corporation in 2001 and Symphony Icon in 2010 and intangible assets associated with the acquisition of Symphony Icon in 2010. For these assets, measurement at fair value in periods subsequent to their initial recognition is applicable if one or more is determined to be impaired.
10

7. Assets Held for Sale
Lexicon’s buildings and land have been reclassified as assets held for sale on the consolidated balance sheet as of September 30, 2014. The Company estimated the fair value of the net assets to be sold at approximately $23.8 million as of September 30, 2014, which represents estimated selling price less costs to sell. This resulted in an impairment loss on the assets held for sale of $13.1 million in the nine months ended September 30, 2014, which was recorded in impairment loss on buildings in the accompanying consolidated statements of comprehensive loss for the three and nine months ended September 30, 2014.
8. Debt Obligations
Mortgage Loan. In April 2004, Lexicon obtained a $34.0 million mortgage on its facilities in The Woodlands, Texas. The mortgage loan originally had a ten-year term with a 20-year amortization and a fixed interest rate of 8.23%. The mortgage was amended in September 2013 to extend the maturity date from April 2014 to April 2017, with the mortgage loan’s monthly payment amount and fixed interest rate each remaining unchanged. The mortgage had a principal balance outstanding of $20.6 million as of September 30, 2014. This entire balance has been classified as current liabilities on the accompanying consolidated balance sheet as of September 30, 2014 as management intends to repay the mortgage when the assets that serve as collateral for the mortgage loan are sold. These assets have been reclassified to assets held for sale as of September 30, 2014, as discussed in Note 7, Assets Held for Sale. The fair value of Lexicon’s mortgage loan approximates its carrying value. The fair value of Lexicon’s mortgage loan is estimated using discounted cash flow analysis, based on the Company’s current incremental borrowing rate.
9. Arrangements with Symphony Icon, Inc.
On June 15, 2007, Lexicon entered into a series of related agreements providing for the financing of the clinical development of certain of its drug candidates, including LX1032 and LX1033, along with any other pharmaceutical compositions modulating the same targets as those drug candidates (the “Programs”). The agreements included a Novated and Restated Technology License Agreement pursuant to which the Company licensed to Symphony Icon, a then wholly-owned subsidiary of Symphony Icon Holdings LLC (“Holdings”), the Company's intellectual property rights related to the Programs. Holdings contributed $45 million to Symphony Icon in order to fund the clinical development of the Programs.
Under a Share Purchase Agreement, dated June 15, 2007, between the Company and Holdings, the Company issued and sold to Holdings 7,650,622 shares of its common stock on June 15, 2007 in exchange for $15 million and an exclusive purchase option (the “Purchase Option”) that gave the Company the right to acquire all of the equity of Symphony Icon, thereby allowing the Company to reacquire all of the Programs. On July 30, 2010, Lexicon entered into an Amended and Restated Purchase Option Agreement with Symphony Icon and Holdings and simultaneously exercised the Purchase Option, thereby reacquiring the Programs. Pursuant to the amended terms of the Purchase Option, Lexicon paid Holdings $10 million on July 30, 2010 and issued 13,237,519 shares of common stock to designees of Holdings on July 30, 2012 in satisfaction of an additional $35 million base payment obligation.
Lexicon also agreed to make up to $45 million in additional contingent payments, which will consist of 50% of any consideration Lexicon receives pursuant to any licensing transaction (a “Licensing Transaction”) under which Lexicon grants a third party rights to commercialize LX1032, LX1033 or other pharmaceutical compositions modulating the same target as those drug candidates (the “LG103 Programs”), subject to certain exceptions. The contingent payments will be due if and when Lexicon receives such consideration from a Licensing Transaction. In the event Lexicon receives regulatory approval in the United States for the marketing and sale of any product resulting from the LG103 Programs prior to entering into a Licensing Transaction for the commercialization of such product in the United States, in lieu of any contingent payment from such a Licensing Transaction, Lexicon will pay Holdings the sum of $15 million and the amount of certain expenses Lexicon incurred after its exercise of the Purchase Option which are attributable to the development of such product, reduced by up to 50% of such sum on account of any contingent payments paid prior to such United States regulatory approval attributable to any such Licensing Transaction outside of the United States with respect to such product. In the event Lexicon makes any such payment upon United States regulatory approval, Lexicon will have no obligation to make subsequent contingent payments attributable to any such Licensing Transactions for the commercialization of such product outside the United States until the proceeds of such Licensing Transactions exceed 50% of the payment made as a result of such United States regulatory approval. The contingent payments may be paid in cash or a combination of cash and common stock, in Lexicon’s discretion, provided that no more than 50% of any contingent payment will be paid in common stock.
Lexicon accounted for the exercise of the Purchase Option and acquisition of Symphony Icon as a business combination. In connection with its acquisition of Symphony Icon, Lexicon paid $10.0 million in cash, and also agreed to pay Holdings additional base and contingent payments as discussed above. The fair value of the base and contingent consideration

Table of Contents
payments was $45.6 million and was estimated by applying a probability-based income approach utilizing an appropriate discount rate. This estimation was based on significant inputs that are not observable in the market, referred to as Level 3 inputs. Key assumptions include: (1) a discount rate of 14% for the base payments; (2) a discount rate of 18% for the contingent payments; and (3) a probability adjusted contingency. The discount rate assumptions have not changed through September 30, 2014, and as programs progress, the probability adjusted contingency is adjusted as necessary. Subsequent changes in the fair value of the Symphony Icon purchase consideration liability are recorded as increase or decrease in fair value of Symphony Icon purchase liability expense in the accompanying consolidated statements of comprehensive loss. During the nine months ended September 30, 2014 and 2013, the fair value of the Symphony Icon purchase consideration liability increased by $0.5 million and $3.1 million, respectively.
10. Commitments and Contingencies
Operating Lease Obligations: A Lexicon subsidiary leases laboratory and office space in Hopewell, New Jersey under an agreement which expires in June 2018. Rent expense is recognized on a straight-line basis over the lease term. Lexicon is the guarantor of the obligations of its subsidiary under this lease. The maximum potential amount of future payments the Company could be required to make under this agreement is $4.0 million as of September 30, 2014. The Company is required to maintain restricted investments to collateralize a standby letter of credit for this lease. The Company had $0.4 million and $0.4 million in restricted investments as collateral as of September 30, 2014 and December 31, 2013, respectively. Additionally, Lexicon leases certain equipment under operating leases.
Legal Proceedings. Lexicon is from time to time party to claims and legal proceedings that arise in the normal course of its business and that it believes will not have, individually or in the aggregate, a material adverse effect on its results of operations, financial condition or liquidity.
11. Collaboration and License Agreements
Lexicon has derived substantially all of its revenues from drug discovery and development collaborations, target validation collaborations for the development and, in some cases, analysis of the physiological effects of genes altered in knockout mice, government grants and contracts, technology licenses, subscriptions to its databases and compound library sales. Revenues generated from third parties under collaborative arrangements are recorded on a gross basis on the consolidated statements of comprehensive loss as Lexicon is the principal participant for these transactions for the purpose of accounting for these arrangements.
12. Restructuring Charges
In January 2014, Lexicon’s board of directors committed to narrow its strategic initiatives and focus resources on its late-stage drug development programs, principally LX4211 for diabetes and telotristat etiprate (LX1032) for carcinoid syndrome, in preparation for the transition to commercialization. The decision resulted in a workforce reduction of approximately 125 employees, primarily in research, discovery and support positions, representing approximately 50% of the Company’s total workforce. The Company completed the majority of the workforce reduction by the end of the second quarter of 2014.
The Company currently expects that the total charges associated with the restructuring which will result in cash expenditures will be approximately $5.7 million (which includes charges for severance of approximately $5.3 million and other restructuring costs of approximately $0.4 million), of which $5.6 million was incurred through September 30, 2014. Of this charge, $4.9 million was recorded in research and development expense and $0.7 million was recorded in general and administrative expense in the accompanying consolidated statement of comprehensive loss for the nine months ended September 30, 2014. In addition, the Company recorded stock-based compensation expense on the acceleration of vesting relating to the restructuring of $0.1 million in the nine months ended September 30, 2014. Future payments of restructuring charges, which have been recorded in accrued liabilities in the accompanying consolidated balance sheet, were $0.4 million as of September 30, 2014.
13. Subsequent Events
On October 21, 2014, Lexicon entered into a License and Collaboration Agreement (the “Agreement”) with Ipsen Pharma SAS (“Ipsen”) for the development and commercialization of Lexicon’s drug candidate LX1032 (telotristat etiprate) outside of the United States, Canada and Japan (the “Licensed Territory”).
12

Table of Contents
Under the Agreement, the Company granted Ipsen an exclusive, royalty-bearing right and license under its patent rights and know-how to commercialize LX1032 in the Licensed Territory. Ipsen is responsible for using diligent efforts to commercialize LX1032 in the Licensed Territory pursuant to a mutually approved commercialization plan.
Subject to certain exceptions, the Company will be responsible for conducting clinical trials required to obtain regulatory approval for LX1032 for carcinoid syndrome in the European Union, including those contemplated by a mutually approved initial development plan, and will have the first right to conduct most other clinical trials of LX1032. The Company is responsible for the costs of all clinical trials contemplated by the initial development plan. The costs of additional clinical trials will be allocated between the parties based on the nature of such clinical trials.
Under the Agreement, Ipsen will pay the Company an upfront payment of $23 million. In addition, the Company is eligible to receive from Ipsen (a) up to an aggregate of approximately $30 million upon the achievement of specified regulatory and commercial launch milestones and (b) up to an aggregate of €72 million upon the achievement of specified sales milestones. The Company is also entitled to tiered, escalating royalties ranging from low twenties to mid-thirties percentages of net sales of LX1032 in the Licensed Territory, subject to a credit for amounts previously paid to Lexicon by Ipsen for the manufacture and supply of such units of LX1032. The Company’s receipt of these payments under the Agreement will trigger its obligation to make certain contingent payments to Holdings pursuant to the Company’s prior arrangement with Holdings for the financing of the clinical development of LX1032 (see Note 9, Arrangements with Symphony Icon, Inc., for more information).
Lexicon and Ipsen will enter into a commercial supply agreement pursuant to which the Company will supply Ipsen’s commercial requirements of LX1032, and Ipsen will pay an agreed upon transfer price for such commercial supply.
13

Table of Contents

Item 2. | Management’s Discussion and Analysis of Financial Condition and Results of Operations

Overview
We are a biopharmaceutical company focused on the development of breakthrough treatments for human disease. We have advanced multiple drug candidates into clinical development. We are presently devoting most of our resources to the development of our two most advanced drug candidates, LX4211 for diabetes and telotristat etiprate for carcinoid syndrome. Our most advanced drug candidates, as well as compounds from a number of additional drug discovery and development programs that we have advanced into various stages of clinical and preclinical development, originated from our own internal drug discovery efforts. These efforts were driven by a systematic, target biology-driven approach in which we used gene knockout technologies and an integrated platform of advanced medical technologies to systematically study the physiological and behavioral functions of almost 5,000 genes in mice and assessed the utility of the proteins encoded by the corresponding human genes as potential drug targets. We identified and validated in living animals, or in vivo, more than 100 targets with promising profiles for drug discovery.
We are working both independently and through strategic collaborations and alliances with third parties to capitalize on our drug target discoveries, and we are pursuing the same strategy for our drug candidates in clinical development. Consistent with this approach, we seek to retain exclusive rights to the benefits of certain drug discovery and development programs by developing and commercializing drug candidates from those programs internally and to collaborate with other pharmaceutical and biotechnology companies with respect to the development and commercialization of drug candidates from other programs, particularly when the collaboration may provide us with access to expertise and resources that we do not possess internally or are complementary to our own. We also seek to collaborate with other pharmaceutical and biotechnology companies, research institutes and academic institutions to capitalize on our drug target discoveries.
We have derived substantially all of our revenues from drug discovery and development collaborations, research collaborations and technology licenses, and will continue to do so for the foreseeable future. To date, we have generated a substantial portion of our revenues from a limited number of sources.
Our operating results and, in particular, our ability to generate additional revenues are dependent on many factors, including our success in establishing new collaborations and licenses, the success rate of our development efforts leading to opportunities for new collaborations and licenses, the timing and willingness of collaborators to commercialize products that would result in milestone payments and royalties and their success in such efforts, and general and industry-specific economic conditions which may affect research and development expenditures. Future revenues from our existing collaborations are uncertain because they depend, to a large degree, on the achievement of milestones and payment of royalties we earn from any future products developed under the collaboration. As a result, we depend, in part, on securing new collaborations and license agreements. Our ability to secure future revenue-generating agreements will depend upon our ability to address the needs of our potential future collaborators and licensees, and to negotiate agreements that we believe are in our long-term best interests. We may determine, as we have with certain of our clinical drug candidates, that our interests are better served by retaining rights to our discoveries and advancing our therapeutic programs to a later stage, which could limit our near-term revenues. Because of these and other factors, our operating results have fluctuated in the past and are likely to do so in the future, and we do not believe that period-to-period comparisons of our operating results are a good indication of our future performance.
Since our inception, we have incurred significant losses and, as of September 30, 2014, we had an accumulated deficit of $1.1 billion. Our losses have resulted principally from costs incurred in research and development, general and administrative costs associated with our operations, and non-cash stock-based compensation expenses associated with stock options and restricted stock granted to employees and consultants. Research and development expenses consist primarily of salaries and related personnel costs, external research costs related to our preclinical and clinical efforts, material costs, facility costs, depreciation on property and equipment, and other expenses related to our drug discovery and development programs. General and administrative expenses consist primarily of salaries and related expenses for executive and administrative personnel, professional fees and other corporate expenses, including information technology, facilities costs and general legal activities. We expect to continue to incur significant research and development costs in connection with the continuing development of our drug candidates. As a result, we will need to generate significantly higher revenues to achieve profitability.
14

Table of Contents
Critical Accounting Policies
The preparation of financial statements in conformity with generally accepted accounting principles requires us to make judgments, estimates and assumptions in the preparation of our consolidated financial statements and accompanying notes. Actual results could differ from those estimates. We believe there have been no significant changes in our critical accounting policies as discussed in our Annual Report on Form 10-K for the year ended December 31, 2013.
Recent Accounting Pronouncements
See Note 4, Recent Accounting Pronouncements, of the Notes to Consolidated Financial Statements, for a discussion of the impact of the new accounting standards on our consolidated financial statements.
Results of Operations
Revenues
Total revenues and dollar and percentage changes as compared to the corresponding periods in the prior year are as follows (dollar amounts are presented in millions):

|  | Three Months Ended September 30, |  | Nine Months Ended September 30,
|  | 2014 |  | 2013 |  | 2014 |  | 2013
Total revenues |  | $ | 0.4 |  |  | $ | 0.2 |  |  | $ | 1.4 |  |  | $ | 0.8 |
Dollar increase |  | $ | 0.2 |  |  |  |  | $ | 0.6 |  |  |
Percentage increase |  | 76 | % |  |  |  | 69 | % |  |

• | Collaborative research – Revenue from collaborative research for the three months ended September 30, 2014 increased from $0.2 million to $0.3 million, and for the nine months ended September 30, 2014 increased from $0.7 million to $1.1 million, primarily due to revenues recognized from collaborations with non-profit institutes supporting the Phase 2 development of LX4211 in type 1 diabetes.

• | Subscription and license fees – Revenue from subscriptions and license fees for the three months ended September 30, 2014 increased to $0.1 million, and for the nine months ended September 30, 2014 increased from $0.1 million to $0.3 million, primarily due to increases in technology license fees.

Research and Development Expenses
Research and development expenses and dollar and percentage changes as compared to the corresponding periods in the prior year are as follows (dollar amounts are presented in millions):

|  | Three Months Ended September 30, |  | Nine Months Ended September 30,
|  | 2014 |  | 2013 |  | 2014 |  | 2013
Total research and development expense |  | $ | 24.1 |  |  | $ | 25.4 |  |  | $ | 69.2 |  |  | $ | 69.4 |
Dollar decrease |  | $ | (1.3 | ) |  |  |  | $ | (0.2 | ) |  |
Percentage decrease |  | (5 | )% |  |  |  | — | % |  |

Research and development expenses consist primarily of third-party and other services principally related to preclinical and clinical development activities, salaries and other personnel-related expenses, facility and equipment costs, stock-based compensation expense, and laboratory supplies costs.

• | Third-party and other services – Third-party and other services for the three months ended September 30, 2014 increased 22% to $16.4 million, and for the nine months ended September 30, 2014 increased 17% to $37.4 million as compared to the corresponding periods in 2013, primarily due to increases in external clinical and preclinical research and development costs. Third-party and other services relate principally to our clinical trial and related development activities, such as preclinical and clinical studies and contract manufacturing.

• | Personnel – Personnel costs for the three months ended September 30, 2014 decreased 37% to $4.1 million, and for the nine months ended September 30, 2014 decreased 7% to $19.3 million, as compared to the corresponding periods

15

Table of Contents
in 2013, primarily due to reductions in our personnel in 2014, partially offset by increased severance costs as a result of those reductions (see Note 12, Restructuring Charges, of the Notes to Consolidated Financial Statements, for more information). Salaries, bonuses, employee benefits, payroll taxes, recruiting and relocation costs are included in personnel costs.

• | Facilities and equipment – Facilities and equipment costs for the three months ended September 30, 2014 decreased 26% to $1.6 million, and for the nine months ended September 30, 2014 decreased 14% to $5.6 million, as compared to the corresponding periods in 2013, primarily due to reductions in laboratory equipment costs and reductions in depreciation expense.

• | Stock-based compensation – Stock-based compensation expense for the three months ended September 30, 2014 decreased 22% to $0.8 million, and for the nine months ended September 30, 2014 decreased 5% to $3.2 million, as compared to the corresponding periods in 2013.

• | Laboratory supplies – Laboratory supplies expense for the three months ended September 30, 2014 decreased 96% to $34,000, and for the nine months ended September 30, 2014 decreased 90% to $0.3 million, as compared to the corresponding periods in 2013, primarily due to reductions in research activities.

• | Other – Other costs for the three months ended September 30, 2014 decreased 16% to $1.1 million, and for the nine months ended September 30, 2014 decreased 10% to $3.4 million, as compared to the corresponding periods in 2013.

Increase in Fair Value of Symphony Icon Liability
The fair value of the Symphony Icon purchase liability decreased by $1.1 million for the three months ended September 30, 2014 and increased by $1.3 million for the three months ended September 30, 2013. The increase in fair value of the Symphony Icon purchase liability was $0.5 million and $3.1 million for the nine months ended September 30, 2014 and 2013, respectively (see Note 9, Arrangements with Symphony Icon, Inc., of the Notes to Consolidated Financial Statements, for more information). The decrease in the three months ended September 30, 2014 was primarily attributable to a reduction in the liability associated with our telotristat etiprate (LX1032) development program in carcinoid syndrome.
General and Administrative Expenses
General and administrative expenses and dollar and percentage changes as compared to the corresponding periods in the prior year are as follows (dollar amounts are presented in millions):

|  | Three Months Ended September 30, |  | Nine Months Ended September 30,
|  | 2014 |  | 2013 |  | 2014 |  | 2013
Total general and administrative expense |  | $ | 4.6 |  |  | $ | 4.7 |  |  | $ | 15.4 |  |  | $ | 13.7 |
Dollar increase (decrease) |  | $ | (0.1 | ) |  |  |  | $ | 1.7 |  |  |
Percentage increase (decrease) |  | (2 | )% |  |  |  | 13 | % |  |

General and administrative expenses consist primarily of salaries and other personnel-related expenses, professional fees such as legal and consulting fees, stock-based compensation expenses, and facility and equipment costs.

• | Personnel – Personnel costs for the three months ended September 30, 2014 was $2.1 million, consistent with the corresponding period in 2013, and for the nine months ended September 30, 2014 increased 19% to $7.7 million, as compared to the corresponding period in 2013, primarily due to increased severance costs as a result of reductions in personnel in 2014 (see Note 12, Restructuring Charges, of the Notes to Consolidated Financial Statements, for more information). Salaries, bonuses, employee benefits, payroll taxes, recruiting and relocation costs are included in personnel costs.

• | Professional fees – Professional fees for the three months ended September 30, 2014 were $1.1 million, consistent with the corresponding period in 2013. Professional fees for the nine months ended September 30, 2014 increased 21% to $3.0 million, as compared to the corresponding period in 2013, primarily due to increased consulting costs in preparation for commercialization.

16

Table of Contents

• | Stock-based compensation – Stock-based compensation expense for the three months ended September 30, 2014 was $0.7 million, consistent with the corresponding period in 2013. Stock-based compensation expense for the nine months ended September 30, 2014 increased 2% to $2.4 million, as compared to the corresponding period in 2013.

• | Facilities and equipment – Facilities and equipment costs for the three months ended September 30, 2014 was

$0.4 million, consistent with the corresponding period in 2013. Facilities and equipment costs for the nine months ended September 30, 2014 decreased four percent to $1.2 million, as compared to the corresponding period in 2013.

• | Other – Other costs for the three months ended September 30, 2014 decreased 13% to $0.3 million, and for the nine months ended September 30, 2014 decreased 3% to $1.0 million, as compared to the corresponding periods in 2013.

Impairment Loss on Buildings
In September 2014, Lexicon determined its buildings and land should be classified as assets held for sale on its consolidated balance sheet. The Company recognized an impairment loss on its buildings of $13.1 million for the three and nine months ended September 30, 2014, as a result of writing down the buildings to the estimated net selling price (see Note 7, Assets Held for Sale, of the Notes to Consolidated Financial Statements, for more information).
Interest Income and Interest Expense
Interest Income. Interest income for the three months ended September 30, 2014 and 2013 was $5,000 and $39,000, respectively, and for the nine months ended September 30, 2014 and 2013 was $17,000 and $136,000, respectively.
Interest Expense. Interest expense for the three months ended September 30, 2014 and 2013 was $0.4 million and $0.5 million, respectively, and for the nine months ended September 30, 2014 and 2013 was $1.4 million and $1.5 million, respectively.
Consolidated Net Loss and Consolidated Net Loss per Common Share
Consolidated Net Loss and Consolidated Net Loss per Common Share. Consolidated net loss increased to $40.5 million in the three months ended September 30, 2014 from $31.7 million in the corresponding period in 2013. Consolidated net loss per common share increased to $0.08 in the three months ended September 30, 2014 from $0.06 in the corresponding period in 2013. Consolidated net loss increased to $97.4 million in the nine months ended September 30, 2014 from $86.7 million in the corresponding period in 2013. Consolidated net loss per common share increased to $0.19 in the nine months ended September 30, 2014 from $0.17 in the corresponding period in 2013.
Our quarterly operating results have fluctuated in the past and are likely to do so in the future, and we believe that quarter-to-quarter comparisons of our operating results are not a good indication of our future performance.
Liquidity and Capital Resources
We have financed our operations from inception primarily through sales of common and preferred stock, contract and milestone payments to us under our drug discovery and development collaborations, target validation, database subscription and technology license agreements, government grants and contracts, and financing obtained under debt and lease arrangements. We have also financed certain of our research and development activities under our agreements with Symphony Icon, Inc. From our inception through September 30, 2014, we had received net proceeds of $987.2 million from issuances of common and preferred stock. In addition, from our inception through September 30, 2014, we received $459.1 million in cash payments from drug discovery and development collaborations, target validation, database subscription and technology license agreements, sales of compound libraries and reagents, and government grants and contracts, of which $446.1 million had been recognized as revenues through September 30, 2014.
As of September 30, 2014, we had $57.9 million in cash, cash equivalents and investments. As of December 31, 2013, we had $129.1 million in cash, cash equivalents and investments. We used cash of $71.2 million in operations in the nine months ended September 30, 2014. This consisted primarily of the consolidated net loss for the period of $97.4 million, partially offset by non-cash charges of impairment of fixed assets of $13.3 million, a net decrease in other operating assets net of liabilities of $5.8 million, $5.6 million related to stock-based compensation expense and $1.7 million related to depreciation expense. Investing activities provided cash of $62.3 million in the nine months ended September 30, 2014, primarily due to net maturities of investments of $60.5 million and proceeds from disposal of property and equipment of $1.8 million. Financing
17

Table of Contents
activities used cash of $1.9 million primarily due to repayment of debt borrowings of $1.3 million and repurchase of common stock of $0.9 million.
Symphony Drug Development Financing Agreements. In June 2007, we entered into a series of related agreements providing for the financing of the clinical development of certain drug programs, including LX1032 and LX1033, along with any other pharmaceutical compositions modulating the same targets as those drug candidates. Under the financing arrangement, we licensed to Symphony Icon, Inc., a then wholly-owned subsidiary of Symphony Icon Holdings LLC, our intellectual property rights related to the programs and Holdings contributed $45 million to Symphony Icon in order to fund the clinical development of the programs. We also issued and sold to Holdings shares of our common stock in exchange for $15 million and received an exclusive option to acquire all of the equity of Symphony Icon, thereby allowing us to reacquire the programs.
Upon the recommendation of Symphony Icon’s development committee, which was comprised of an equal number of representatives from us and Symphony Icon, Symphony Icon’s board of directors had the right to require us to pay Symphony Icon up to $15 million for Symphony Icon’s use in the development of the programs in accordance with the specified development plan and related development budget. Symphony Icon’s board of directors requested that we pay Symphony Icon $9.3 million under the agreement, all of which was paid prior to the exercise of the purchase option in July 2010.
In July 2010, we entered into an amended and restated purchase option agreement with Symphony Icon and Holdings and simultaneously exercised our purchase option. Pursuant to the amended terms of the purchase option, we paid Holdings $10 million in July 2010 and issued 13,237,519 shares of common stock to designees of Holdings in July 2012 in satisfaction of an additional $35 million base payment obligation.
We also agreed to make up to $45 million in additional contingent payments, which will consist of 50% of any consideration we receive pursuant to any licensing transaction under which we grant a third party rights to commercialize LX1032, LX1033 or other pharmaceutical compositions modulating the same target as those drug candidates, which we refer to as the “LG103 programs,” subject to certain exceptions. The contingent payments will be due if and when we receive such consideration from such a licensing transaction. In the event we receive regulatory approval in the United States for the marketing and sale of any product resulting from the LG103 programs prior to entering into such a licensing transaction for the commercialization of such product in the United States, in lieu of any contingent payment from such a licensing transaction, we will pay Holdings the sum of $15 million and the amount of certain expenses we incurred after our exercise of the purchase option which are attributable to the development of such product, reduced by up to 50% of such sum for the amount of any contingent payments paid prior to such United States regulatory approval attributable to any such licensing transaction outside of the United States with respect to such product. In the event we make any such payment upon United States regulatory approval, we will have no obligation to make subsequent contingent payments attributable to any such licensing transactions for the commercialization of such product outside the United States until the proceeds of such licensing transactions exceed 50% of the payment made as a result of such United States regulatory approval.
The contingent payments may be paid in cash or a combination of cash and common stock, in our discretion, provided that no more than 50% of any contingent payment will be paid in common stock.
Texas Institute for Genomic Medicine. In July 2005, we received an award from the Texas Enterprise Fund for the
creation of a knockout mouse embryonic stem cell library containing 350,000 cell lines for the Texas Institute for Genomic
Medicine, or TIGM, using our proprietary gene trapping technology, which we completed in 2007. We also equipped TIGM
with the bioinformatics software required for the management and analysis of data relating to the library. The Texas Enterprise Fund made an additional award to the Texas A&M University System for the creation of facilities and infrastructure to house
the library.
Under the terms of our award, we are responsible for the creation of a specified number of jobs beginning in 2012,
reaching an aggregate of 1,616 new jobs in Texas by December 31, 2016. We will receive credits against those job obligations
based on funding received by TIGM and certain related parties from sources other than the State of Texas. We will also receive
credits against those jobs obligations for any surplus jobs we create. We may be required to repay the state a portion of the
award if we fail to meet those job obligations. Subject to these credits, if we fail to create the specified number of jobs, the
State may require us to repay $2,415 for each job we fall short beginning in 2013. Our maximum aggregate exposure for such
payments, if we fail to create any new jobs, is approximately $14.2 million, including $1.5 million through 2014, without giving effect to any credits to which we may be entitled.
Facilities. In April 2004, we obtained a $34.0 million mortgage on our facilities in The Woodlands, Texas. The mortgage loan originally had a ten-year term with a 20-year amortization and a fixed interest rate of 8.23%. The mortgage was amended in September 2013 to extend the maturity date from April 2014 to April 2017, with the mortgage loan’s monthly
18

Table of Contents
payment amount and fixed interest rate each remaining unchanged. The mortgage had a principal balance outstanding of $20.6 million as of September 30, 2014. The buildings and land that serve as collateral for the mortgage have been classified as assets held for sale as of September 30, 2014, and management has reclassified all of the mortgage loan as current liabilities as the loan will be repaid upon sale of the buildings and land.
In May 2002, our subsidiary Lexicon Pharmaceuticals (New Jersey), Inc. leased a 76,000 square-foot laboratory and office space in Hopewell, New Jersey. Effective December 31, 2012, this lease was amended to decrease the space to approximately 42,000 square feet. The term of the amended lease extends until June 30, 2018. The amended lease provides for escalating yearly base rent payments starting at $836,000 and increasing to $941,000 in the final year of the lease. We are the guarantor of the obligations of our subsidiary under the lease.
Our future capital requirements will be substantial and will depend on many factors, including our ability to obtain drug discovery and development collaborations and other collaborations and technology license agreements, the amount and timing of payments under such agreements, the level and timing of our research and development expenditures, market acceptance of our products, the resources we devote to developing and supporting our products and other factors. Our capital requirements will also be affected by any expenditures we make in connection with license agreements and acquisitions of and investments in complementary technologies and businesses. We expect to devote substantial capital resources to continue our development efforts, to expand our support and product development activities, and for other general corporate activities. We believe that our current unrestricted cash and investment balances and cash and revenues we expect to derive from drug discovery and development collaborations, other collaborations and technology licenses and other sources will be sufficient to fund our operations for at least the next 12 months. During or after this period, if cash generated by operations is insufficient to satisfy our liquidity requirements, we will need to sell additional equity or debt securities or obtain additional credit arrangements. Additional financing may not be available on terms acceptable to us or at all. The sale of additional equity or convertible debt securities may result in additional dilution to our stockholders. Although we have previously been successful in obtaining financing through our equity securities offerings, we may not be able to do so in the future. If we are not able to secure adequate additional financings we may be forced to make reductions in spending and/or liquidate assets where possible. Any of these actions could harm our business and our results of operations.
Disclosure about Market Risk
We are exposed to limited market and credit risk on our cash equivalents which have maturities of three months or less
at the time of purchase. We maintain a short-term investment portfolio which consists of U.S. Treasury bills, money market accounts, and certificates of deposit that mature three to 12 months from the time of purchase, which we believe are subject to limited market and credit risk. We currently do not hedge interest rate exposure or hold any derivative financial instruments in our investment portfolio.
We had approximately $57.9 million in cash and cash equivalents and short-term investments as of September 30, 2014. Subsequent to September 30, 2014, we entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of our drug candidate LX1032 (telotristat etiprate) outside of the United States, Canada and Japan, which provides for Ipsen to pay us an upfront payment of $23 million (see Note 13, Subsequent Events, of the Notes to Consolidated Financial Statements, for more information). We believe that our current unrestricted cash and investment balances and cash and revenues we expect to derive from drug discovery and development collaborations, other collaborations and technology licenses and other sources will be sufficient to fund our operations for at least the next 12 months.
We have operated primarily in the United States and substantially all sales to date have been made in U.S. dollars. Accordingly, we have not had any material exposure to foreign currency rate fluctuations.
Item 3. Quantitative and Qualitative Disclosures About Market Risk
See “Disclosure about Market Risk” under “Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations” for quantitative and qualitative disclosures about market risk.
Item 4. Controls and Procedures
Our principal executive officer and principal financial officer have concluded that our disclosure controls and procedures (as defined in rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934) are effective to ensure that the information required to be disclosed by us in the reports we file under the Securities Exchange Act is gathered, analyzed and disclosed with adequate timeliness, accuracy and completeness, based on an evaluation of such controls and procedures as of the end of the period covered by this report.
Subsequent to our evaluation, there were no significant changes in internal controls or other factors that could significantly affect internal controls, including any corrective actions with regard to significant deficiencies and material weaknesses.
19

Table of Contents
Part II -- Other Information

Item 1. | Legal Proceedings

We are from time to time party to claims and legal proceedings that arise in the normal course of our business and that we believe will not have, individually or in the aggregate, a material adverse effect on our results of operations, financial condition or liquidity.

Item 1A. | Risk Factors

The following risks and uncertainties are important factors that could cause actual results or events to differ materially from those indicated by forward-looking statements. The factors described below are not the only ones we face and additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations.
Risks Related to Our Need for Additional Financing and Our Financial Results

• | We will need additional capital in the future and, if it is unavailable, we will be forced to significantly curtail or cease our operations. If it is not available on reasonable terms, we will be forced to obtain funds by entering into financing agreements on unattractive terms.

• | We have a history of net losses, and we expect to continue to incur net losses and may not achieve or maintain profitability.

• | Our operating results have been and likely will continue to fluctuate, and we believe that period-to-period comparisons of our operating results are not a good indication of our future performance.

Risks Related to Development of Our Drug Candidates

• | We have not proven our ability to successfully develop and commercialize our drug candidates.

• | Clinical testing of our drug candidates in humans is an inherently risky and time-consuming process that may fail to demonstrate safety and efficacy, which could result in the delay, limitation or prevention of regulatory approval.

Risks Related to Regulatory Approval of Our Drug Candidates

• | Our drug candidates are subject to a lengthy and uncertain regulatory process that may not result in the necessary regulatory approvals, which could adversely affect our ability to commercialize products.

• | If our potential products receive regulatory approval, we or our collaborators will remain subject to extensive and rigorous ongoing regulation.

Risks Related to Commercialization of Products

• | The commercial success of any products that we may develop will depend upon the degree of market acceptance of our products among physicians, patients, health care payors, private health insurers and the medical community.

• | If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to market and sell our drug candidates, we may be unable to generate product revenues.

• | If we are unable to obtain adequate coverage and reimbursement from third-party payors for any products that we may develop, our revenues and prospects for profitability will suffer.

• | Current and future healthcare laws and regulations may negatively affect our revenues and prospects for profitability.

• | Our competitors may develop products that make our products obsolete.

• | We may not be able to manufacture our drug candidates in commercial quantities, which would prevent us from commercializing our drug candidates.

20

Table of Contents
Risks Related to Our Relationships with Third Parties

• | We are dependent in many ways upon our collaborations with major pharmaceutical companies. If we are unable to establish new collaborations, if milestones are not achieved under our collaborations or if our collaborators’ efforts fail to yield pharmaceutical products on a timely basis, our opportunities to generate revenues and earn royalties will be reduced.

• | Conflicts with our collaborators could jeopardize the success of our collaborative agreements and harm our product development efforts.

• | We rely on third parties to carry out drug development activities.

• | We lack the capability to manufacture materials for preclinical studies, clinical trials or commercial sales and rely on third parties to manufacture our drug candidates, which may harm or delay our product development and commercialization efforts.

Risks Related to Our Intellectual Property

• | If we are unable to adequately protect our intellectual property, third parties may be able to use our products and technologies, which could adversely affect our ability to compete in the market.

• | We may be involved in patent litigation and other disputes regarding intellectual property rights and may require licenses from third parties for our planned preclinical and clinical development and commercialization activities. We may not prevail in any such litigation or other dispute or be able to obtain required licenses.

• | We have not sought patent protection outside of the United States for some of our inventions, and some of our licensed patents only provide coverage in the United States. As a result, our international competitors could be granted foreign patent protection with respect to our discoveries.

• | We may be subject to damages resulting from claims that we, our employees or independent contractors have wrongfully used or disclosed alleged trade secrets of their former employers.

Risks Related to Employees, Advisors and Facilities Operations

• | The loss of key personnel or the inability to attract and retain additional personnel could impair our ability to expand our operations.

• | Our collaborations with outside scientists may be subject to restriction and change.

• | Security breaches may disrupt our operations and harm our operating results.

• | Because most of our operations are located at a limited number of facilities, the occurrence of a disaster could significantly disrupt our business.

Risks Related to Environmental and Product Liability

• | We use hazardous chemicals and radioactive and biological materials in our business. Any claims relating to improper handling, storage or disposal of these materials could be time consuming and costly.

• | We face potential product liability exposure in excess of our insurance coverage.

Risks Related to Our Common Stock

• | Invus, L.P., Invus C.V. and their affiliates own a controlling interest in our outstanding common stock and may have interests which conflict with those of our other stockholders.

• | Invus has additional rights under our stockholders’ agreement with Invus, L.P. which provides Invus with substantial influence over certain significant corporate matters.

• | Our stock price may be extremely volatile.

21

Table of Contents

• | We may engage in future acquisitions, which may be expensive and time consuming and from which we may not realize anticipated benefits.

• | Future sales of our common stock may depress our stock price.

• | If we are unable to meet Nasdaq continued listing requirements, Nasdaq may take action to delist our common stock.

For additional discussion of the risks and uncertainties that affect our business, see “Item 1A. Risk Factors” included in our annual report on Form 10-K for the year ended December 31, 2013 as filed with the Securities and Exchange Commission.

Item 6. | Exhibits

Exhibit No. |  | Description
†10.1 | — | License and Collaboration Agreement, dated October 21, 2014, with Ipsen Pharma SAS
31.1 | — | Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2 | — | Certification of Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1 | — | Certification of Principal Executive and Principal Financial Officers Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS | — | XBRL Instance Document
101.SCH | — | XBRL Taxonomy Extension Schema Document
101.CAL | — | XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF | — | XBRL Taxonomy Extension Definition Linkbase Document
101.LAB | — | XBRL Taxonomy Extension Label Linkbase Document
101.PRE | — | XBRL Taxonomy Extension Presentation Linkbase Document
† | Confidential treatment has been requested for a portion of this exhibit. The confidential portions of this exhibit have been omitted and filed separately with the Securities and Exchange Commission.

22

Table of Contents
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

|  | Lexicon Pharmaceuticals, Inc.
Date: | November 6, 2014 | By: | /s/ Lonnel Coats
|  |  | Lonnel Coats
|  |  | President and Chief Executive Officer

Date: | November 6, 2014 | By: | /s/ Jeffrey L. Wade
|  |  | Jeffrey L. Wade
|  |  | Executive Vice President, Corporate Development and Chief Financial Officer

23

Table of Contents
Index to Exhibits

Exhibit No. |  | Description
†10.1 | — | License and Collaboration Agreement, dated October 21, 2014, with Ipsen Pharma SAS
31.1 | — | Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2 | — | Certification of Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1 | — | Certification of Principal Executive and Principal Financial Officers Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS | — | XBRL Instance Document
101.SCH | — | XBRL Taxonomy Extension Schema Document
101.CAL | — | XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF | — | XBRL Taxonomy Extension Definition Linkbase Document
101.LAB | — | XBRL Taxonomy Extension Label Linkbase Document
101.PRE | — | XBRL Taxonomy Extension Presentation Linkbase Document
† | Confidential treatment has been requested for a portion of this exhibit. The confidential portions of this exhibit have been omitted and filed separately with the Securities and Exchange Commission.

24